H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Constellation Pharmaceuticals (CNST) today and set a price target of $75.00. The company’s shares closed last Thursday at $44.04.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 10.2% and a 45.9% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Proteostasis Therapeutics, and Deciphera Pharmaceuticals.
Currently, the analyst consensus on Constellation Pharmaceuticals is a Strong Buy with an average price target of $56.29, which is a 27.6% upside from current levels. In a report issued on May 6, Oppenheimer also assigned a Buy rating to the stock with a $55.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $59.49 and a one-year low of $6.01. Currently, Constellation Pharmaceuticals has an average volume of 388K.
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CNST in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The company utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product candidates include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA.
